8-K false 0001607678 0001607678 2026-07-29 2026-07-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2026 Viking Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9920 Pacific Heights Blvd, Suite 500 San Diego , California 92121 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: 858 704-4660 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. On July 29, 2026, we issued a press release reporting our financial results for the second quarter ended June 30, 2026 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 99.1 Press release issued July 29, 2026, reporting financial results for the second quarter ended June 30, 2026 and providing a corporate update. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viking Therapeutics, Inc. Date: July 29, 2026 By: /s/ Brian Lian, Ph.D. President and Chief Executive Officer ( Principal Executive Officer )

Viking Therapeutics, Inc. reported its Q2 2026 financial results on July 29, 2026, disclosing revenue, net income, and operational updates including pipeline product developments and forward guidance.

On July 29, 2026, Viking Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026. The press release includes detailed information regarding the company's financial performance during the quarter, including revenue figures, net income, and any significant operational updates. Key highlights may include changes in revenue year-over-year, important developments in pipeline products, and updated guidance for future quarters. This filing serves as a necessary compliance to disclose financial results to the public and investors.

Viking Therapeutics, Inc.

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means